Bioventus (BVS) Common Equity (2020 - 2026)

Bioventus (BVS) has 7 years of Common Equity data on file, last reported at $234.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 26.3% year-over-year to $234.3 million; the trailing twelve-month figure through Mar 2026 stood at $234.3 million (up 26.3% YoY), and the FY2025 full-year result was $184.1 million, down 0.81% from the prior year.
• Common Equity for Q1 2026 stood at $234.3 million, up from $184.1 million in the prior quarter.
• Across five years, Common Equity topped out at $593.8 million in Q2 2022 and bottomed at $166.1 million in Q3 2025.
• The 5-year median for Common Equity is $221.1 million (2023), against an average of $277.7 million.
• The widest annual swing landed in 2022, when Common Equity soared 169.91%; it then plunged 60.59% in 2023.
• A 5-year view of Common Equity shows it stood at $412.2 million in 2022, then slumped by 46.36% to $221.1 million in 2023, then declined by 16.06% to $185.6 million in 2024, then slipped by 0.81% to $184.1 million in 2025, then climbed by 27.25% to $234.3 million in 2026.
• The last three Common Equity figures came in at $234.3 million (Q1 2026), $184.1 million (Q4 2025), and $166.1 million (Q3 2025), per Business Quant data.

Peer Comparison